TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36139910

Group type: EXPERIMENTAL
Intervention: 10.5 g mixture of trehalose, spermidine, nicotinamide, and polyphenols
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study: 36143102

Group type: EXPERIMENTAL
Intervention: Single antiplatelets (SAPT)
Number of subjects: 80426

Group type: EXPERIMENTAL
Intervention: Dual antiplatelets (DAPT)
Number of subjects: 80426

Group type: EXPERIMENTAL
Intervention: Vitamin-K antagonists (VKA)
Number of subjects: 80426

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 80426

Group type: EXPERIMENTAL
Intervention: Both antiplatelets and oral anticoagulation
Number of subjects: 80426

Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy
Number of subjects: 80426
Study: 36143388

Group type: EXPERIMENTAL
Intervention: Continuous amnioinfusion with Amnion Flush Solution (up to 100 mL/h, 2400 mL/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard PPROM therapy (antibiotics and corticosteroids)
Number of subjects: 68
Study: 36144220

Group type: EXPERIMENTAL
Intervention: Machine Learning predictive algorithm (boosted ensemble algorithm XGBoost)
Number of subjects: 958
Study: 36146760

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs)
Number of subjects: 89
Study: 36146847

Group type: EXPERIMENTAL
Intervention: N-based ELISA test system
Number of subjects: 0

Group type: COMPARATOR
Intervention: RBD-based serology tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-based test systems
Number of subjects: 0
Study: 36147300

Group type: EXPERIMENTAL
Intervention: Vitamins A, β-carotene, and pantothenic acid measured in human milk samples
Number of subjects: 147
Study: 36147777

Group type: EXPERIMENTAL
Intervention: Old fibroadipogenic progenitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Young mice
Number of subjects: 0
Study: 36147862

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 36148206

Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 3
Study: 36148253

Group type: EXPERIMENTAL
Intervention: Current or ex-smokers (23 of 82 CS cases, 28.0%)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 87
Study: 36148362

Group type: EXPERIMENTAL
Intervention: Perceived partner support
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Couple-based interventions
Number of subjects: 152
Study: 36148649

Group type: EXPERIMENTAL
Intervention: PPG-based algorithm for detecting undiagnosed AF using wearable Fitbit devices.
Number of subjects: 455699
Study: 36148691

Group type: EXPERIMENTAL
Intervention: Self-reported computerized history taking (CHT) programme Clinical Expert Operating System (CLEOS)
Number of subjects: 54
Study: 36148823

Group type: COMPARATOR
Intervention: Resting state EEG functional connectivity in theta band
Number of subjects: 180

Group type: COMPARATOR
Intervention: Resting state EEG functional connectivity in beta band
Number of subjects: 180

Group type: COMPARATOR
Intervention: Cortical functional connectivity in painful DPN patients
Number of subjects: 180

Group type: COMPARATOR
Intervention: Individual significant functional connections in all frequency bands
Number of subjects: 180
Study: 36148886

Group type: EXPERIMENTAL
Intervention: Irradiation in the morning (06.00-10.00 am)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Irradiation in the afternoon (04.00-06.00 pm)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Initial haemoglobin (Hb) level
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinical tumour size
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Circadian cycle (morning vs. afternoon)
Number of subjects: 56
Study: 36148895

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 1395
Study: 36148919

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 36149413

Group type: EXPERIMENTAL
Intervention: Germline variants identified in patients with positive family history (8 of 19 patients, 42.1%)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Germline variants identified in sporadic patients (23 of 226 patients, 10.2%)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Somatic variants identified in tested individuals (20 of 119 tested individuals, 16.8%)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Overall variants of interest identified at the germline level (12.2% of patients)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Overall variants of interest identified at the somatic level (7.8% of patients)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Coexisting germline and somatic variants (0.4% of patients)
Number of subjects: 245
Study: 36149729

Group type: EXPERIMENTAL
Intervention: Dating apps (Jack'D)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Social media sites (Instagram)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Information search sites (Bing)
Number of subjects: 254
Study: 36149737

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control group (no immediate intervention)
Number of subjects: 40
Study: 36149743

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ) for SMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SP+AQ and piperaquine-resistance markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMC implementation model
Number of subjects: 0
Study: 36149832

Group type: EXPERIMENTAL
Intervention: Darvadstrocel (24-mL intralesional injection, 120×106 cells)
Number of subjects: 22
Study: 36150047

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative/unknown thrombophilia
Number of subjects: 0
Study: 36150050

Group type: EXPERIMENTAL
Intervention: Enasidenib 100mg daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enasidenib maintenance therapy
Number of subjects: 23
Study: 36150053

Group type: EXPERIMENTAL
Intervention: IAA-first autoantibody predictors
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: GADA-first autoantibody predictors
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Progression from single to multiple autoantibodies
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Progression to diabetes
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Progression to multiple autoantibodies
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Progression from multiple autoantibodies to diabetes
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Newly reported SNPs
Number of subjects: 8502
Study: 36150143

Group type: EXPERIMENTAL
Intervention: Valemetostat 200 mg/day orally until progressive disease or unacceptable toxicity
Number of subjects: 25
Study: 36150208

Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain (GWG)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Recommended gestational weight gain (GWG)
Number of subjects: 184
Study: 36150365

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity tertiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measured biomarkers
Number of subjects: 0
Study: 36150668

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine (CoronaVac) administered in two doses (28-days interval) with a booster at day 210.
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: TNF inhibitors (TNFi)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: SSZ+TNFi combination
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Third dose of vaccine (D69-D240)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: TNFi
Number of subjects: 194
Study: 36150750

Group type: EXPERIMENTAL
Intervention: Whole-image ganglion cell complex (wiGCC) thickness
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Whole-image vessel density (wiVD)
Number of subjects: 238
Study: 36150926

Group type: EXPERIMENTAL
Intervention: Ustekinumab (IV and/or SC administration)
Number of subjects: 1673
Study: 36151216

Group type: EXPERIMENTAL
Intervention: CD7-targeting CAR-T cells (RD13-01)
Number of subjects: 12
Study: 36151335

Group type: EXPERIMENTAL
Intervention: Emergency source control intervention (< 2 h of diagnosis)
Number of subjects: 2621

Group type: EXPERIMENTAL
Intervention: Urgent source control intervention (2-6 h of diagnosis)
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Delayed source control intervention (> 6 h of diagnosis)
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Septic shock
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Late-onset hospital-acquired peritonitis
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Failed source control evidenced by persistent inflammation at day 7
Number of subjects: 2621

Group type: COMPARATOR
Intervention: Appropriate empiric therapy
Number of subjects: 2621
Study: 36151773

Group type: EXPERIMENTAL
Intervention: Metformin in combination with VIT (vincristine, irinotecan, and temozolomide) at Dose Level 4 (1666 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metformin in combination with VIT
Number of subjects: 26
Study: 36151945

Group type: EXPERIMENTAL
Intervention: Adult clinic sites
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pediatric clinic sites
Number of subjects: 0
Study: 36151975

Group type: EXPERIMENTAL
Intervention: Cannabis-specific risk factors in permissive environments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Permissiveness of the cannabis environment
Number of subjects: 0
Study: 36152116

Group type: EXPERIMENTAL
Intervention: Subjects with hypertension
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subjects with hyperlipidemia
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subjects with diabetes
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Subjects with obesity
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 387
Study: 36152144

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day, 3 weeks on/1 week off) plus letrozole (2.5 mg/day)
Number of subjects: 554
Study: 36152216

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Tralokinumab with or without TCS
Number of subjects: 719
Study: 36152218

Group type: EXPERIMENTAL
Intervention: Eculizumab-treated patients with aHUS and malignant hypertension
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Not-treated patients with malignant hypertension
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Not-treated patients with aHUS
Number of subjects: 1097
Study: 36152227

Group type: EXPERIMENTAL
Intervention: LumiraDx SARS-CoV-2 and Flu A/B Test
Number of subjects: 283
Study: 36152767

Group type: EXPERIMENTAL
Intervention: 3P machine learning model (platelet count, bilirubin, international normalised ratio)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: 5P machine learning model (platelet count, bilirubin, activated partial thromboplastin time, gamma-glutamyltransferase, choline-esterase)
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: 3P machine learning model
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: 5P machine learning model
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Liver stiffness measurement
Number of subjects: 1232
Study: 36152902

Group type: EXPERIMENTAL
Intervention: Thoracic Spinal Nerve Neuromodulation Therapy
Number of subjects: 0
Study: 36152897

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor agents
Number of subjects: 10206

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 10206

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 10206

Group type: EXPERIMENTAL
Intervention: Azathioprine/thiopurines
Number of subjects: 10206

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Number of subjects: 10206

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 10206
Study: 36153018

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for time to pregnancy
Number of subjects: 1931

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1931
Study: 36153561

Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0
Study: 36153609

Group type: EXPERIMENTAL
Intervention: Manuka honey sinus rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard sinus rinse (control)
Number of subjects: 30
Study: 36154291

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36154854

Group type: EXPERIMENTAL
Intervention: Capillary blood samples
Number of subjects: 36

Group type: COMPARATOR
Intervention: Venous blood samples
Number of subjects: 36
Study: 36155150

Group type: EXPERIMENTAL
Intervention: Plasma l-carnitine
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Plasma l-carnitine (highest tertile)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 646

Group type: COMPARATOR
Intervention: Control group (matched controls free of recurrent cardiovascular events)
Number of subjects: 646
Study: 36155347

Group type: EXPERIMENTAL
Intervention: Paid advertisements on Facebook
Number of subjects: 407769

Group type: EXPERIMENTAL
Intervention: Unpaid posts on the MAGENTA Facebook page
Number of subjects: 407769

Group type: EXPERIMENTAL
Intervention: Overall Facebook outreach (paid and unpaid)
Number of subjects: 407769

Group type: EXPERIMENTAL
Intervention: Women aged ≥65 years
Number of subjects: 407769

Group type: EXPERIMENTAL
Intervention: Social media outreach
Number of subjects: 407769
Study: 36155396

Group type: EXPERIMENTAL
Intervention: Digital Artificial Intelligence System
Number of subjects: 60
Study: 36155490

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiangiogenic agents (sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy based regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy with anti-PD-1/PD-L1 or anti-CTLA4 antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of new strategies
Number of subjects: 0
Study: 36155747

Group type: EXPERIMENTAL
Intervention: Endotracheal Intubation
Number of subjects: 142
Study: 36156099

Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily with pembrolizumab 200 mg intravenously every 3 weeks and one of 7 chemotherapy regimens
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg orally twice daily with pembrolizumab and chemotherapy
Number of subjects: 70
Study: 36157553

Group type: EXPERIMENTAL
Intervention: Low/no-charge coronary artery calcium (CAC) scoring
Number of subjects: 52151
Study: 36157681

Group type: EXPERIMENTAL
Intervention: 30-min eye covering
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: 60-min eye covering
Number of subjects: 228

Group type: COMPARATOR
Intervention: Programmed education only (C group)
Number of subjects: 228
Study: 36157895

Group type: EXPERIMENTAL
Intervention: Almitrine (n=89)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (n=92)
Number of subjects: 181
Study: 36158516

Group type: EXPERIMENTAL
Intervention: Albumin-to-globulin ratio (AGR)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low AGR
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 85

Group type: COMPARATOR
Intervention: Neutrophil to lymphocyte ratio (NLR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Platelet to lymphocyte ratio (PLR)
Number of subjects: 85
Study: 36158588

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy with resin yttrium-90 microspheres (SIRT) followed by gemcitabine 1,000 mg/m²
Number of subjects: 24
Study: 36158638

Group type: EXPERIMENTAL
Intervention: Plasma circulating-tumor DNA testing using a DNA-based mutation panel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tissue testing per standard of care including comprehensive next-generation sequencing (NGS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cohort A (plasma testing)
Number of subjects: 20
Study: 36158690

Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy (etoposide plus platinum) followed by sintilimab maintenance treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sintilimab maintenance treatment
Number of subjects: 13
Study: 36158692

Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with S-1 plus oxaliplatin (SOX)
Number of subjects: 32
Study: 36158813

Group type: EXPERIMENTAL
Intervention: AHA-ABI
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: FLOW-ABI
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Simplified ABI measurement
Number of subjects: 188
Study: 36159253

Group type: EXPERIMENTAL
Intervention: Active Herts programme
Number of subjects: 717
Study: 36159928

Group type: EXPERIMENTAL
Intervention: Electrophysiological measurements with ERG flash and pattern
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: EEG data
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Sleep settings
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Clinical assessments
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography for retinal structure and microvascularization
Number of subjects: 140
Study: 36159943

Group type: EXPERIMENTAL
Intervention: Episodic resonance paced breathing (eRPB) at 0.1 Hz
Number of subjects: 77

Group type: COMPARATOR
Intervention: Faster paced breathing sham at 0.23 Hz
Number of subjects: 77
Study: 36160038

Group type: EXPERIMENTAL
Intervention: Mindfulness practice using a mobile app for 3 weeks (10 min/day)
Number of subjects: 80
Study: 36160138

Group type: EXPERIMENTAL
Intervention: AIDA mAIDs Registry
Number of subjects: 337
Study: 36160773

Group type: EXPERIMENTAL
Intervention: Standing-still posture
Number of subjects: 42
Study: 36161271

Group type: EXPERIMENTAL
Intervention: gBRCAm carriers
Number of subjects: 20624

Group type: COMPARATOR
Intervention: BRCA wild-type (WT)
Number of subjects: 20624

Group type: COMPARATOR
Intervention: not-tested (NT)
Number of subjects: 20624

Group type: EXPERIMENTAL
Intervention: gBRCAm carriers in triple-negative subgroup
Number of subjects: 20624

Group type: EXPERIMENTAL
Intervention: gBRCAm carriers in HR+/HER2 negative cancers
Number of subjects: 20624
Study: 36161320

Group type: EXPERIMENTAL
Intervention: lovo-cel gene therapy (bb1111; LentiGlobin)
Number of subjects: 0
Study: 36161511

Group type: EXPERIMENTAL
Intervention: Short-term androgen deprivation therapy (ADT)
Number of subjects: 25
Study: 36161783

Group type: EXPERIMENTAL
Intervention: ExtraTrees Classifier model
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: lite model with 16 variables
Number of subjects: 106
Study: 36161875

Group type: EXPERIMENTAL
Intervention: Increased doses of inhaled corticosteroids (ICS)
Number of subjects: 1774

Group type: COMPARATOR
Intervention: Stable doses of inhaled corticosteroids (ICS) (placebo)
Number of subjects: 1774
Study: 36162011

Group type: EXPERIMENTAL
Intervention: CMV-specific immunoglobulins (CMV-Ig) administered to 10 patients in addition to standard antiviral prophylaxis.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard antiviral prophylaxis without CMV-Ig administered to 39 patients.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CMV-Ig group
Number of subjects: 49
Study: 36162059

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 483
Study: 36162227

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 559
Study: 36162849

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients
Number of subjects: 668

Group type: COMPARATOR
Intervention: Potential kidney donors
Number of subjects: 668

Group type: COMPARATOR
Intervention: Community-dwelling employed adults
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients before transplantation
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients at 12 months after transplantation
Number of subjects: 668
Study: 36163044

Group type: EXPERIMENTAL
Intervention: Postpartum depression (PPD) assessment using the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Comparison of observed PPD rate during lockdown to pre-pandemic rate
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combined EPDS> 12 or PPQ > 6 scores
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Factors associated with EPDS> 12
Number of subjects: 164
Study: 36163163

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin (area under the curve 2) and weekly paclitaxel 80 mg/m2 in cohort 1 (triple-negative)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and/or paclitaxel in cohort 2 (hormone receptor-positive)
Number of subjects: 40
Study: 36163415

Group type: EXPERIMENTAL
Intervention: Clopidogrel with modification (n=39)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Clopidogrel without modification (n=167)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Antiplatelet modification based on PRU value
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: PRU cutoff values
Number of subjects: 206
Study: 36163427

Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 0
Study: 36163530

Group type: EXPERIMENTAL
Intervention: Community member reviews
Number of subjects: 578

Group type: COMPARATOR
Intervention: Scientific reviews
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Community reviewer comments
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Published intervention articles
Number of subjects: 578
Study: 36163561

Group type: EXPERIMENTAL
Intervention: 3D-laparoscopic pancreaticoduodenectomy with stented pancreaticogastrostomy and Roux-en-Y gastroenterostomy
Number of subjects: 347